Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 17/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4203592 | 1.00 | KEAP1 (0.61) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL4203042 | 1.00 | KEAP1 (0.61) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL2788610 | 0.98 | KEAP1 (0.59) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL14587261 | 0.96 | KEAP1 (0.56) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL4243455 | 0.92 | KEAP1 (0.50) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL4243228 | 0.92 | KEAP1 (0.50) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL27749385 | 0.92 | KEAP1 (0.50) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL13928640 | 0.89 | CHRM3 (0.57) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL2656123 | 0.86 | CHRM3 (0.55) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL26134188 | 0.86 | CHRM3 (0.55) | KEAP1NFE2L2CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542232-B2 | Process for production of glycopyrronium tosylate | JOURNEY MEDICAL CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210002219-A1 | PROCESS FOR PRODUCTION OF GLYCOPYRRONIUM TOSYLATE | SWK FUNDING LLC | 2021-01-07 | — | — | US | disclosed |
| US-20190225580-A1 | PROCESS FOR PRODUCTION OF GLYCOPYRRONIUM TOSYLATE | DERMIRA, INC. | 2019-07-25 | — | — | US | disclosed |
| US-10294201-B2 | Process for production of glycopyrronium tosylate | DERMIRA, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180186735-A1 | PROCESS FOR PRODUCTION OF GLYCOPYRRONIUM TOSYLATE | SWK FUNDING LLC | 2018-07-05 | — | — | US | disclosed |
| US-9926270-B2 | Process for production of glycopyrronium tosylate | DERMIRA, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20090233965-A1 | Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233965-A1 | Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233965-A1 | Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| CN-101490003-A | New alkyl esters of cyclic amino alcohols with muscarinic m3 receptor antagonist activity, useful for treating e.g. chronic bronchial obstruction, asthma and overactive bladder | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | CN | disclosed |
| US-20090042942-A1 | Muscarinic Receptor Antagonists | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042942-A1 | Muscarinic Receptor Antagonists | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042942-A1 | Muscarinic Receptor Antagonists | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| EP-2013172-A1 | NEW ALKYL ESTERS OF CYCLIC AMINO ALCOHOLS WITH MUSCARINIC M3 RECEPTOR ANTAGONIST ACTIVITY, USEFUL FOR TREATING E.G. CHRONIC BRONCHIAL OBSTRUCTION, ASTHMA AND OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| CN-101163673-A | Novel muscarinic receptor antagonists | ASTRAZENECA AB (SE) | 2008-04-16 | — | — | CN | disclosed |
| EP-1874727-A1 | NEW MUSCARINIC RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007123465-A1 | NEW ALKYL ESTERS OF CYCLIC AMINO ALCOHOLS WITH MUSCARINIC M3 RECEPTOR ANTAGONIST ACTIVITY, USEFUL FOR TREATING E.G. CHRONIC BRONCHIAL OBSTRUCTION, ASTHMA AND OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007123465-A1 | NEW ALKYL ESTERS OF CYCLIC AMINO ALCOHOLS WITH MUSCARINIC M3 RECEPTOR ANTAGONIST ACTIVITY, USEFUL FOR TREATING E.G. CHRONIC BRONCHIAL OBSTRUCTION, ASTHMA AND OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2006112778-A1 | NEW MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-10-26 | — | — | WO | disclosed |
| WO-1994012029-A1 | USE OF FUSED RING CYCLOPENTANONES AND CYCLOPENTENONES IN CONTROLLING PLANT GROWTH | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042942-A1 | Muscarinic Receptor Antagonists | CHRM2, CHRM3, CHRM1 | KEAP1 2761/4885NFE2L2 4636/4885CHRM3 2/4885 |
| US-20210002219-A1 | PROCESS FOR PRODUCTION OF GLYCOPYRRONIUM TOSYLATE | TPO, GYPA, THRA | KEAP1 4660/4885NFE2L2 4800/4885CHRM3 1482/4885 |
| US-20090233965-A1 | Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder | CHRM3, CHRM2, CHRM1 | KEAP1 3069/4885NFE2L2 3953/4885CHRM3 1/4885 |
| US-20180186735-A1 | PROCESS FOR PRODUCTION OF GLYCOPYRRONIUM TOSYLATE | TPO, GYPA, THRA | KEAP1 4660/4885NFE2L2 4800/4885CHRM3 1482/4885 |
| US-10294201-B2 | Process for production of glycopyrronium tosylate | TPO, GYPA, THRA | KEAP1 4660/4885NFE2L2 4800/4885CHRM3 1482/4885 |
| US-20190225580-A1 | PROCESS FOR PRODUCTION OF GLYCOPYRRONIUM TOSYLATE | TPO, GYPA, THRA | KEAP1 4660/4885NFE2L2 4800/4885CHRM3 1482/4885 |
| US-11542232-B2 | Process for production of glycopyrronium tosylate | TPO, GYPA, THRA | KEAP1 4660/4885NFE2L2 4800/4885CHRM3 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.